Compare Quest Diagnostics Inc (DGX) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs BIO-TECHNE Corp — how do they compare? Quest Diagnostics Inc trades at $205.45 (market cap $22.95B), while BIO-TECHNE Corp trades at $71.23 (market cap $11.12B). The key difference: Quest Diagnostics Inc is far larger — about 2.1× BIO-TECHNE Corp's market cap, and Quest Diagnostics Inc pays the higher dividend (1.66%). Which is the better fit depends on your goals.
| DGX | TECH | |
|---|---|---|
Market Cap | $22.95B | $11.12B |
Sector | Health | Health |
52-Week High | $216.02 | $71.38 |
52-Week Low | $166.42 | $43.31 |
Enterprise Value | $28.97B | $11.20B |
Dividend Yield | 1.66% | 0.45% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
